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In Brief
Skeletal muscle consists of a mix of fast
and slow fibers, but the molecular mech-
anisms regulating fiber type remain
incompletely understood. Ehlers et al.
show that the transcription factor NFATc1
regulates fiber type balance and is
required for fast-to-slow switching in
response to exercise. They also show
that NFATc1 inhibits fast fiber gene
expression by blocking the interaction of
p300 and MyoD, a crucial regulator of
the fast fiber phenotype. The results
establish amolecular mechanism for fiber
type control.
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Skeletal muscle comprises a heterogeneous popula-
tionof fiberswith importantphysiological differences.
Fast fibers are glycolytic and fatigue rapidly. Slow
fibers utilize oxidative metabolism and are fatigue
resistant. Muscle diseases such as sarcopenia and
atrophy selectively affect fast fibers, but the molecu-
lar mechanisms regulating fiber type-specific gene
expression remain incompletely understood. Here,
we show that the transcription factor NFATc1 con-
trols fiber type composition and is required for fast-
to-slow fiber type switching in response to exercise
in vivo. Moreover, MyoD is a crucial transcriptional
effector of the fast fiber phenotype, and we show
that NFATc1 inhibits MyoD-dependent fast fiber
gene promoters by physically interacting with the
N-terminal activation domain of MyoD and blocking
recruitment of the essential transcriptional coactiva-
tor p300. These studies establish amolecularmecha-
nism for fiber type switching through direct inhibition
of MyoD to control the opposing roles of MyoD and
NFATc1 in fast versus slow fiber phenotypes.
INTRODUCTION
Skeletal muscle is composed of a heterogeneous population of
muscle fibers that display several distinct properties (Schiaffino
and Reggiani, 2011). Type I (slow twitch) muscle fibers utilize
oxidativemetabolism, are rich inmitochondria, display increased
vascularization, and are fatigue resistant. Type II (fast twitch)
fibers utilize glycolytic metabolism and fatigue rapidly (Schiaffino
and Reggiani, 2011). Adult skeletal muscle can undergo conver-
sion between these fiber types in response to exercise training or
the pattern of motor neuron activity (Pette, 1998).
The basic helix-loop-helix (bHLH) transcription factor MyoD
possesses the remarkable ability to convert most cell types
into multinucleated, contractile myotubes through forced ex-
pression in cell culture and functions as an essential regulator
of myogenesis (Tapscott, 2005). MyoD is also reutilized for mul-
tiple distinct roles in postnatal muscle, including fiber type con-
trol (Legerlotz and Smith, 2008). MyoD is expressed more highlyCell Rein fast fibers than in slow fibers, andMyod1-null mice show shifts
in fiber type of fast muscle toward a slower phenotype (Hughes
et al., 1997; Macharia et al., 2010). Conversely, overexpression
of an active form of MyoD in muscle results in a slow-to-fast fiber
type conversion (Ekmark et al., 2007). MyoD binds DNA as a
heterodimer with members of the E-protein family of bHLH pro-
teins through the interaction of the HLH domains (Tapscott,
2005). The N terminus of MyoD encodes an activation domain
that also contains a motif referred to as the C/H domain, which
has been proposed to confer ‘‘pioneer’’ activity to MyoD through
interactions with the histone acetyltransferase p300/CBP and
other chromatin remodeling enzymes (Berkes and Tapscott,
2005; Tapscott, 2005).
Nuclear factor of activated T cell (NFAT) proteins comprise a
family of five transcription factors (NFATc1, NFATc2, NFATc3,
NFATc4, and NFAT5) that are regulated by the phosphatase cal-
cineurin (Hogan et al., 2003). Calcineurin signaling plays a key
role in the maintenance of the slow fiber phenotype in adult mus-
cle (Hogan et al., 2003). NFAT proteins are known to regulate
slow fiber genes in cell culture systems (Chin et al., 1998; Wu
et al., 2000), but a role for NFAT proteins in control of fiber
type in vivo has not yet been established. Although NFATc1 is
the predominant NFAT isoform expressed in adult skeletal mus-
cle (Rana et al., 2008), studies interrogating its role in muscle
in vivo have been limited because nfatc1-null mice die at embry-
onic day 12.5 due to cardiac valve defects (Hogan et al., 2003).
Here, we inactivated nfatc1 exclusively in skeletal muscle. We
demonstrate that NFATc1 is required in vivo for the proper bal-
ance of slow type I and fast type II fibers and for fast-to-slow fiber
switching in response to exercise. Unexpectedly, we found that
NFATc1 inhibits expression of MyoD-dependent fast fiber genes
in a DNA-binding independent fashion. NFATc1 inhibits MyoD
function by physically interacting with and blocking the essential
interaction of the MyoD N-terminal activation domain with p300
and subsequent activation of MyoD target genes. These studies
demonstrate that NFATc1 is an essential regulator of fiber type-
specific gene expression and fiber type switching in response to
exercise and establish NFATc1 as a negative regulator of MyoD.
RESULTS
MyoD Function Is Negatively Regulated by NFATc1
The Mef2c gene is a direct transcriptional target of MyoD via a
skeletal-muscle-specific promoter (Dodou et al., 2003; Wangports 8, 1639–1648, September 25, 2014 ª2014 The Authors 1639
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et al., 2001). To gain additional insight into the regulation of
Mef2c in skeletal muscle, we analyzed its promoter for
conserved transcription factor binding sites. In addition to the
previously described MyoD binding sites (E boxes), we also
identified five consensus NFAT binding sites (Figure S1). There-
fore, we examined the effect of several NFAT proteins onMef2c
promoter activity in the presence and absence of MyoD (Fig-
ure 1A). NFATc1, NFATc3, and NFATc4 alone had no effect on
the Mef2c promoter, whereas MyoD strongly transactivated
theMef2c reporter plasmid (Figure 1A). Strikingly, MyoD-depen-
dent transactivation was strongly repressed by NFATc1, but
not by NFATc3 or NFATc4 (Figure 1A; data not shown), suggest-
ing a role specifically for NFATc1 in the inhibition of MyoD
transactivation.
To determine if NFATc1 repressed the Mef2c promoter
through the NFAT sites, we generated a Mef2c reporter
construct encompassing the MyoD-dependent E boxes but
lacking all of the NFATc1-binding sites (Figure S1, nucleotides
shown in red). This reporter was strongly transactivated when
cotransfected with MyoD, and surprisingly, MyoD-dependent
activation of the reporter was still profoundly reduced when an
NFATc1 expression plasmid was also cotransfected (Figure 1B).
These results demonstrate that NFATc1 inhibition of MyoD
activity does not require the NFAT cis-regulatory elements and
suggest that it may occur through DNA-independent interaction
with MyoD.
To further investigate the inhibition of MyoD-dependent
transactivation by NFATc1, we examined the activation of two
other established MyoD-dependent target promoters from the
myogenin and mrf4 genes (Black et al., 1995; Edmondson
et al., 1992) in the presence or absence of NFATc1 (Figures 1C
and 1D). Importantly, MyoD strongly transactivated each of
these other reporters, and this transactivation was repressed
by NFATc1, but not by NFATc3 (Figures 1C and 1D).
We next examined whether NFATc1 influenced MyoD-medi-
ated myogenic conversion (Figures 1E–1I). Control transfected
C3H10T1/2 cells did not express myosin heavy chain (MyHC)
nor did they formmultinucleated myotubes (Figure 1E). Similarly,
transfection of an NFATc1 expression vector alone did not result
in myotube formation or MyHC expression (Figure 1F). As ex-
pected, transfection of a MyoD expression vector resulted in
robust myogenic conversion as shown by the formation of
MyHC-positive myotubes (Figure 1G). Coexpression of NFATc1
with MyoD resulted in a nearly complete inhibition of myotube
formation andmyosin heavy chain expression (Figure 1H). West-
ern blot analyses of fastMyHC (Figure 1I) showed nearly identical
results: control and NFATc1 transfected C3H10T1/2 cells had noFigure 1. NFATc1 Inhibits MyoD Activity
(A, C, and D) MyoD transactivated the Mef2c (A), myogenin (C), and mrf4 (D) pro
(B) A Mef2c skeletal muscle promoter lacking NFAT sites (Figure S1) was trans
(lane 4). Results in (A–D) are reported as the mean fold activation plus SEM from
(E–I) C3H10T1/2 cells were transfected, differentiated, and assessed for fast M
transfected with the pRK5 vector (E), NFATc1 alone (F), MyoD alone (G), or Myo
expression and myotube formation (white arrowheads). Nuclei were countersta
C3H10T1/2 cells transfected with vector alone (lane 1), NFATc1 alone (lane 2), My
loading control on the same cell lysates. Nearly identical results were obtained in
See also Figure S1.
Cell Reexpression of MyHC (Figure 1I) whereas MyoD induced robust
MyHC expression (Figure 1I, lane 3), and this induction was pro-
foundly inhibited by coexpression of NFATc1 (Figure 1I, lane 4).
Generation of a Skeletal-Muscle-Specific Knockout of
nfatc1
Although NFATc1 expression in skeletal muscle is well estab-
lished (Hogan et al., 2003), we confirmed NFATc1 expression
in the nuclei of both slow and fast myofibers, and we found
that NFATc1 and MyoD were coexpressed in skeletal muscle
(Figure S2). Therefore, to test the role of NFATc1 in the regulation
of MyoD-dependent genes in vivo and to determine the function
of NFATc1 in skeletal muscle, we generated mice with nfatc1
loss of function in skeletal muscle (Figure 2A). Skeletal-muscle-
specific nfatc1 knockout mice (nfatc1SkMKO) were born at
Mendelian frequency (Figure S3A) and survived to adulthood
with no overt phenotype (data not shown). We observed greater
than 80% reduction in nfatc1 mRNA levels in the muscles of
nfatc1SkMKO mice compared to nfatc1flox/+ (control) mice by
quantitative PCR (qPCR) and western blot analyses (Figures
S3B and S3C). We did not observe any significant differences
in growth, body mass, or muscle weight between control and
nfatc1SkMKO mice (Figures S3D and S3E).
Expression of MyoD-Dependent Genes Is Increased in
the Absence of NFATc1 In Vivo
The observation that NFATc1 strongly repressed MyoD-depen-
dent activation of the Mef2c, myogenin, and mrf4 promoters
(Figure 1) prompted us to examine expression of the endoge-
nous genes in nfatc1SkMKO and control mice (Figure 2B).
Importantly, expression of Mef2c, mrf4, and myogenin was
significantly increased in the absence of NFATc1 in vivo (Fig-
ure 2B). Other known MyoD target genes, including desmin,
nestin, muscle creatine kinase, and the Myod1 gene itself, also
showed significantly increased expression in the skeletal muscle
of nfatc1SkMKO mice compared to controls (Figure 2B). These
data support the idea that NFATc1 represses MyoD-dependent
gene activation in vivo.
NFATc1 Controls Skeletal Muscle Fiber Type
Composition and Switching in Response to Exercise
Given the role of calcineurin-NFAT signaling in skeletal muscle
fiber type regulation based on studies performed in cell culture
model systems (Chin et al., 1998; Wu et al., 2000), we reasoned
that mice lacking NFATc1 in skeletal muscle might have altered
fiber type composition. To test this hypothesis, we used meta-
chromatic ATPase staining to label slow and fast fibers in themoters (lane 2); NFATc1 (c1) significantly inhibited activation (lane 5).
activated by MyoD (lane 3), and coexpression of NFATc1 inhibited activation
four independent transfections.
yHC (MY32) by immunofluorescence (E–H) and western blot (I). Cells were
D plus NFATc1 (H). Coexpression of NFATc1 blocked MyoD-induced MyHC
ined with DAPI in all panels. (I) Western blot analysis of myosin induction in
oD alone (lane 3), and NFATc1 plus MyoD (lane 4). a-tubulin was examined as a
six independent experiments.
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soleus and found that nfatc1SkMKO mice had a lower percentage
of slow fibers than control mice (Figures 2C and 2E; 34.5%
versus 44.5%; p = 0.006). These findings support a role for
NFATc1 in establishing or maintaining the slow fiber phenotype
and provide genetic evidence for NFATc1 in the regulation of
fiber type composition in vivo.
The conversion of fast fibers to slow fibers can be induced in
mice in response to a continuous period of voluntary exercise
(Pette, 1998). The mouse soleus muscle contains a significant
percentage of slow fibers under normal conditions and is
extensively studied as a model for understanding signals
involved in fiber type regulation. Therefore, we examined the
fiber type composition of the soleus muscle following a 7-day
period of voluntary exercise. Control mice showed a significant
increase in the percentage of slow fibers in response to exercise
(Figures 2C and 2D; Figure 2E, compare lanes 1 and 3; p =
0.019). In contrast, nfatc1SkMKO mice did not undergo fiber
type switching in response to exercise (Figure 2C0 and 2D0; Fig-
ure 2E, compare lanes 2 and 4; p = 0.137). In spite of the reduced
percentage of slow fibers in the soleus muscle, we observed no
differences between nfatc1SkMKO and control mice in time or
distance run (Figures S3F and S3G). We also found a significant
increase in the expression of several fast fiber genes in
nfatc1SkMKO soleusmuscle in comparison to control muscle (Fig-
ure 2F, light blue bars). Increased expression of fast myosin in
the soleus muscles of nfatc1SkMKO mice compared to controls
was also observed by western blot (Figure 2G). Interestingly,
we did not observe significant changes in slow fiber gene
expression at the transcript level (Figure 2F, dark blue bars),
even though we observed a significant reduction in the percent-
age of slow fibers in nfatc1SkMKO muscles (Figures 2C and 2E)
and in the amount of slow myosin by western blot (Figure 2G).
The observation that slow myosin protein expression decreased
whereas mRNA was not significantly changed suggests that
posttranscriptional mechanisms may be involved in maintaining
the appropriate myosin expression in muscle. Our observations
also suggest the possibility that NFATc1 might function in skel-
etal muscle fiber type control by repressing expression of
MyoD-dependent fast muscle genes.
NFATc1 Physically Interacts with MyoD
To gain further insight into the repression of MyoD activity by
NFATc1, we tested whether NFATc1 physically interacts with
MyoD (Figure 3). NFATc1 was efficiently coimmunoprecipitated
by anti-MyoD in cells expressing MyoD, but not in control trans-
fected cells (Figure 3A). We found that the DNA-binding domain
(DBD) of NFATc1 (REL domain) was necessary and sufficient for
the physical interaction with MyoD (Figure 3B). Similarly, we
examined the interaction of various domains of MyoD with
NFATc1 (Figures 3C–3E). MyoD truncations that contained the
N terminus and bHLH region but lacked the C terminus (DC)
were efficiently immunoprecipitated by anti-NFATc1 (Figure 3C).
In contrast, MyoD truncations lacking the N terminus (DN) failed
to interact with NFATc1 (Figure 3D), suggesting that the MyoD
N terminus was required for interaction with NFATc1. Consistent
with this notion, we found that the MyoD N-terminal activation
domain alone (MyoD 1–101) was coimmunoprecipitated by
anti-NFATc1 (Figure 3E). These experiments demonstrate that1642 Cell Reports 8, 1639–1648, September 25, 2014 ª2014 The Authe MyoD N terminus is necessary and sufficient for interaction
with NFATc1.
NFATc1 Inhibits MyoD Transactivation
We considered several possible MyoD functions that might be
inhibited by NFATc1. Notably, MyoD nuclear localization was
unaffected by coexpression with either wild-type or a constitu-
tively active form of NFATc1 (Figure S4). Likewise, NFATc1 did
not affect MyoD-E12 DNA binding in an in vitro electrophoretic
mobility shift assay (EMSA), which also suggested that MyoD-
E12 dimerization was unlikely to be affected by NFATc1 because
dimerization is prerequisite to efficient DNA binding in EMSA
(Figure S5).
As an additional test of the effect of NFATc1 on MyoD-E pro-
tein function, we employed a modified mammalian two-hybrid
assay in which the E12 bHLH domain (lacking a transactivation
domain) was fused to the GAL4 DBD and was used as bait for
recruitment and activation by full-length MyoD (Figure 4A,
model). Coexpression of MyoD with GAL4-E12 bHLH resulted
in robust activation of the GAL4-dependent upstream activating
sequence (UAS) reporter due to MyoD-E12 bHLH dimerization
and activation by MyoD (Figure 4A). NFATc1 coexpression
potently inhibited the effect of MyoD on the reporter (Figure 4A,
compare lanes 6 and 7), whereas NFATc3 had no effect (Fig-
ure 4A, lane 8). We also used GAL4-MyoD bHLH as bait and
the E protein bHLH domain fused to the VP16 activation domain
as prey (Figure 4B, model). GAL4-MyoD bHLH lacks a transacti-
vation domain and therefore had no effect on reporter activation
on its own, but coexpression of E12-VP16 resulted in potent acti-
vation (Figure 4B). Importantly, coexpression of NFATc1 had no
effect on activation by E12-VP16 (Figure 4B, compare lanes 6
and 7), suggesting that NFATc1 does not inhibit MyoD-E protein
dimerization. Taken together, the results in Figures 4A and 4B
support the idea that NFATc1 inhibits transactivation by MyoD.
As an explicit test of the effect of NFATc1 on MyoD-mediated
transactivation, full-length MyoD was fused directly to the GAL4
DBD and activation of a UAS-dependent reporter was examined
(Figure 4C, model). MyoD was sufficient to activate the reporter
more than 10-fold, and coexpression of NFATc1 significantly in-
hibited activation of the reporter (Figure 4C, compare lanes 3
and 4). Importantly, the MyoD N terminus, which encodes the
major transactivation domain of MyoD (Berkes and Tapscott,
2005; Tapscott, 2005), was also sufficient to activate the reporter
when fused to the GAL4 DBD, and NFATc1 coexpression signif-
icantly inhibited that activation (Figure 4C, compare lanes 5
and 6). This observation, combined with the observation that
NFATc1 specifically interacted with the N terminus of MyoD
(Figure 3), suggests that a direct protein-protein inhibitory inter-
action accounts for the mechanism underlying NFATc1-medi-
ated inhibition of MyoD transactivation.
NFATc1 Disrupts MyoD Interaction with p300
TheN terminus ofMyoD interacts with the histone acetyltransfer-
ase p300, and that interaction is essential for MyoD-mediated
conversion of fibroblasts into myotubes (Puri et al., 1997; Sartor-
elli et al., 1997). Therefore, we tested the hypothesis that NFATc1
might inhibit MyoD-p300 interaction (Figure 5A). Cotransfection
of MyoD and p300 resulted in efficient coimmunoprecipitationthors
Figure 2. NFATc1 Is Required for Normal Fiber Type Composition, Gene Expression, and Exercise-Induced Fiber Type Switching In Vivo
(A) Strategy used to generate skeletal-muscle-specific knockout of nfatc1.
(B) qPCR analysis of MyoD target gene expression in the soleus muscles of adult control (wild-type [wt]) and nfatc1SkMKO (cko) mice. *p < 0.05; **p < 0.01. Data
shown represent the mean ratio of expression in nfatc1SkMKO compared to wild-type muscle plus SEM for six mice of each genotype.
(C–E) Metachromatic ATPase staining of soleus muscles showed a higher percentage of slow fibers (dark blue) in control (wt; C and D) than in nfatc1SkMKO
(cko; C0 and D0) in the absence of exercise (no run; C and C0) or following 7 days of voluntary exercise (run; D and D0). The scale bars represent 100 mm. (E) No
run wt mice had a significantly higher percentage of slow fibers than unexercised nfatc1SkMKO mice (compare lanes 1 and 2; p < 0.01). Following exercise, the
percentage of slow fibers in wt soleus increased from 45% to 50% (compare lanes 1 and 3; p < 0.05); the percentage of slow fibers in the soleus of nfatc1SkMKO
mice showed no statistically significant difference (compare lanes 2 and 4). Data are presented as the mean percentage of slow fibers plus SEM for six mice in
each group.
(F) qPCR analysis of fast (light blue bars) and slow (dark blue bars) fiber gene expression in the soleus muscles of unexercised control (wt) and nfatc1SkMKO (cko)
male mice. Data are shown as the mean ratio of expression in nfatc1SkMKO to wild-type muscle plus SEM for six mice of each genotype. *p < 0.05; n.s., not
significant.
(G) Western blot analysis of fast and slow myosin expression from wt (lanes 1 and 2) and nfatc1SkMKO (cko; lanes 3 and 4) soleus muscles. a-tubulin was
examined as a loading control on the same cell lysates.
See also Figures S2 and S3.
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Figure 3. NFATc1 Physically Interacts with the N Terminus of MyoD
(A and B) C3H10T1/2 cells were transfected with the indicated plasmids, and
lysates were analyzed by immunoprecipitation (IP)-western blot. Sample in-
puts, IgG antibody controls, and beads-only controls are indicated. MyoD
physically interacted with full-length NFATc1 (A, lane 8). IP, anti-MyoD;
western, anti-NFATc1. MyoD interacts with the DNA-binding domain (DBD) of
NFATc1 (B, lane 6). Expression plasmids for full-length MyoD and FLAG-tag-
ged truncation fragments of NFATc1, encoding the N terminus (N), catalytic
domain (cat), or DBD were cotransfected. IP, anti-MyoD; western, anti-FLAG.
(C–E) Expression plasmids for full-length NFATc1 and FLAG-tagged MyoD
lacking the C terminus (C), FLAG-tagged MyoD lacking the N terminus (D), or a
Myc-tagged N-terminal fragment of MyoD (E) were cotransfected. IP, anti-
NFATc1; western, anti-FLAG (C and D) and anti-Myc (E). MyoDDC was effi-
ciently coimmunoprecipitated by anti-NFATc1 (C, lane 7). The N terminus of
MyoD alone (MyoD(N)) was coimmunoprecipitated with NFATc1 (E, lane 7).
MyoDDN was not coimmunoprecipitated by anti-NFATc1 (D, lane 7).
1644 Cell Reports 8, 1639–1648, September 25, 2014 ª2014 The Auof MyoD with anti-p300 (Figure 5A, lane 4, red asterisk). Impor-
tantly, coexpression of NFATc1 inhibited p300-MyoD interaction
(Figure 5A, lane 7, red asterisk).
The inhibition of MyoD-p300 interaction by NFATc1 suggested
the possibility that NFATc1 might be blocking recruitment of
p300 to MyoD-dependent target genes in vivo. To test this
idea, we examined p300 occupancy at MyoD-dependent tar-
gets, fast fiber genes, and slow fiber genes from wild-type and
nfatc1SkMKO soleus muscles (Figure 5B). Strikingly, p300 occu-
pancy at the Mef2c, myogenin, and mrf4 promoters was higher
in nfatc1SkMKO mice than in controls (Figure 5B). In addition,
p300 occupancy was higher at fast fiber genes in the absence
of NFATc1 but was unchanged at slow fiber genes (Figure 5B).
These data support a role for NFATc1 in blocking MyoD recruit-
ment of p300 in vivo.
Previous studies have suggested that p300 is rate limiting for
MyoD-mediated conversion of fibroblasts to myotubes (Sartor-
elli et al., 1997). Therefore, we predicted that addition of excess
p300 might be sufficient to rescue the NFATc1-mediated inhibi-
tion of MyoD. In the absence of p300, NFATc1 nearly completely
inhibited MyoD-mediated conversion of C3H10T1/2 cells into
myotubes (Figures 5C and 5C0). Remarkably, addition of p300
in the presence of MyoD and NFATc1 partially overcame the
NFATc1-mediated inhibition of MyoD conversion (Figures 5D0
and 5E0). Quantification of the MyoD conversion in the presence
and absence of excess p300 showed that statistically significant
rescue of NFATc1 inhibition of MyoD occurred in a dose-depen-
dent fashion (Figure 5F). Together, these data strongly support
the notion that NFATc1 inhibits MyoD by disrupting interaction
of p300 with the MyoD N-terminal transcriptional activation
domain.
DISCUSSION
Regulation of Skeletal Muscle Fiber Type by NFATc1
Inhibition of MyoD
NFAT proteins are major effectors of calcineurin signaling, and
calcineurin-dependent transcriptional pathways are involved in
the control of skeletal muscle fiber type (Chin et al., 1998;
Naya et al., 2000; Parsons et al., 2003, 2004). Several prior
studies have supported a role for the NFAT family in the activa-
tion of slow fiber genes and concomitant repression of fast fiber
genes in cell-culture-based studies and through gain-of-functionthors
Figure 4. NFATc1 Inhibits the MyoD N-Ter-
minal Activation Domain
C3H10T1/2 cells were transfected with the indi-
cated GAL4(DBD) fusion protein expression
plasmids and the UAS reporter plasmid pG5E1b-
luciferase. Full-length MyoD, NFATc1 (c1),
NFATc3 (c3), E12-VP16, or parental expres-
sion vector (dashes) were also cotransfected as
indicated.
(A) MyoD dimerization with GAL4-E12(bHLH)
caused potent activation (lane 6), which was
significantly inhibited by NFATc1 (lane 7).
(B) E12-VP16-GAL4-MyoD(bHLH) dimers strongly
activated the pG5E1b-luciferase reporter (lane 6),
and this was not inhibited by NFATc1 (lane 7).
(C) Fusion of full-length MyoD or the N-terminal
fragment of MyoD (MyoD(N)) to the GAL4 DBD
resulted in potent activation of the UAS reporter
due to the strong activation domains of MyoD.
Coexpression of NFATc1 significantly inhibited the
MyoD activation domain (compare lanes 3 and 4
and lanes 5 and 6). Results in all panels are re-
ported as the mean fold activation plus SEM from
four independent transfections. Models depicting
the mammalian two-hybrid (A and B) and one-
hybrid (C) assays are shown to the right of their
respective graphs.
See also Figures S4 and S5.in vivo muscle electroporation studies (Calabria et al., 2009;
McCullagh et al., 2004; Rana et al., 2008). Interestingly, delivery
of a slow pattern of electrical activity mimicking endurance
exercise to fast muscle fibers causes fast-to-slow fiber type
switching (Pette, 1998; Schiaffino and Reggiani, 2011) and also
results in the inactivation of MyoD (Ekmark et al., 2007). Given
the opposing functions of MyoD and NFAT in the control
of fast versus slow fiber gene expression in response to elec-
trical stimulation (Calabria et al., 2009; Ekmark et al., 2007;
McCullagh et al., 2004) and our findings that NFATc1 potently
represses MyoD function, we hypothesize that NFATc1 pro-
motes the slow fiber phenotype in part through repression of
MyoD activity. Interestingly, all myogenic bHLH proteins contain
an N-terminal activation domain but differ in whether or not they
contain an N-terminal C/H domain (Berkes and Tapscott, 2005;Cell Reports 8, 1639–1648, SepTapscott, 2005). Thus, it would be inter-
esting to determine whether NFATc1
also interacts with other members of the
MyoD family and whether these interac-
tions influence gene expression or fiber
type control.
Distinct Roles for NFAT Isoforms in
Skeletal Muscle
In the studies here, we show clearly
that NFATc1 blocks MyoD activity,
whereas NFATc3 does not. We also
show that NFATc1 physically associates
with MyoD. Previous studies have sug-
gested that NFATc3 also physicallyassociates with MyoD and that this association promotes
MyoD activity (Armand et al., 2008; Delling et al., 2000). In
contrast, we did not observe cooperative activation of the
myogenin promoter by NFATc3 and MyoD (Figure 1), nor did
we observe augmentation of MyoD activity in the myotube
conversion assay by NFATc3 (data not shown). Together, these
observations suggest that the physical interaction of MyoD with
NFATc1 versus NFATc3 likely results in distinct coactivator and
corepressor interactions by different NFAT family members.
Our studies also suggest that NFATc1 may be the primary
NFAT isoform downstream of calcineurin responsible for regu-
lating skeletal muscle fiber type because loss-of-function
studies for the other nfat genes found no defects in skeletal
muscle fiber type (Graef et al., 2001; Horsley et al., 2001; Keg-
ley et al., 2001).tember 25, 2014 ª2014 The Authors 1645
Figure 5. NFATc1 Disrupts MyoD Interaction with p300
C3H10T1/2 cells were cotransfected with MyoD and p300 plus or minus NFATc1, and lysates were analyzed by anti-p300 immunoprecipitation followed by anti-
MyoD western blot (A), or cells were allowed to differentiate and were analyzed for myotube formation (C–E).
(A) MyoD coimmunoprecipitates with p300 (lane 4, red asterisk); this interaction was inhibited by NFATc1 (lane 7, red asterisk). IgG isotype controls and sample
inputs are indicated.
(B) ChIP-qPCR analyses for p300 occupancy of a negative control genomic region and the promoter regions of seven genes from wt and cko soleus muscles, as
indicated. Data from three independent experiments on different animals are shown as the percentage of input genomic DNA plus SEM. Enrichment for each
promoter was calculated by the DCt method and normalized to input. Black bars, immunoprecipitation with isotype control IgG; white bars, immunoprecipitation
with anti-p300 antibody.
(C–F) MyoD converted fibroblasts into multinucleated, MyHC+ (green staining) myotubes (white arrowheads) (C); conversion was potently inhibited by NFATc1
(C0). (D and E) Addition of p300 expression plasmid partially overcame the inhibitory effect of NFATc1 on MyoD (white arrowheads in D0 and E0). The amount of
p300 expression plasmid (mg) is indicated in parentheses. (F) Conversion to myotubes was quantified as the fraction of MY32+ cells in the MyoD alone control.
MyHC+ cells were counted in ten fields from three mice for each condition. Relative myogenic conversion plus SD is indicated. The amount (mg) of each
transfected expression plasmid is indicated.
Data in (B) and (F) were analyzed by two-way ANOVA test with Bonferroni’s multiple comparison post hoc analysis.Implications for NFATc1 Regulation of MyoD in
Sarcopenia and Muscle Atrophy
Slow type I fibers remain relatively constant in size with age,
whereas fast type II muscle fiber size diminishes (Porter et al.,1646 Cell Reports 8, 1639–1648, September 25, 2014 ª2014 The Au1995). The atrophy that occurs in fast muscle fibers during sarco-
penia is believed to play amajor role in the pathogenesis of frailty
and the functional impairment that occurs with old age or
extended bed rest (Evans, 2010). Basal expression of myogenicthors
bHLH genes increases in proportion to the degree of sarcopenia
in senescent muscle (Kim et al., 2005). Our findings that NFATc1
promotes the slow fiber phenotype and that nfatc1SkMKO mice
have increased expression of myogenin, mrf4, and Myod1 sug-
gest that NFATc1 might play a role in maintaining slow fibers
in aging muscle. Thus, NFATc1 and its upstream and down-
stream regulatory pathways, including calcineurin signaling,
might represent interesting therapeutic targets for modulating
the balance of slow and fast fibers in afflictions such as muscle
atrophy and sarcopenia.
EXPERIMENTAL PROCEDURES
Knockout and Transgenic Mice
mef2c-73k-Cre and nfatc1flox/flox mice have been described (Aliprantis et al.,
2008; Heidt and Black, 2005). To generate nfatc1+/D mice, male nfatc1flox/flox
mice were crossed to female Mef2c-AHF-Cre mice (Rojas et al., 2008).
When crossed from the female,Mef2c-AHF-Cre functions as a universal dele-
ter line, resulting in Cre-dependent recombination in all cells in all offspring
(B.L.B., unpublished data). Voluntary exercise assays using 42-day-old male
mice were conducted as described previously (Jaehnig et al., 2006). All
experiments using animals were reviewed and approved by the University of
California, San Francisco Institutional Animal Care and Use Committee and
complied with institutional and federal guidelines.
RNA Extraction, Real-Time qPCR, and ChIP
Total RNA was prepared frommouse tissues using the RNeasy Fibrous Tissue
Mini Kit (QIAGEN). RNA was treated for 1 hr at 37C with DNaseI, followed by
cDNA synthesis using the Omniscript RT kit (QIAGEN). For chromatin immuno-
precipitation (ChIP), soleusmuscles of 42-day-old control and nfatc1SkMKO run
mice were frozen, minced, and fixed with 1% formaldehyde in PBS for 10 min
at 37C. ChIP was performed as previously described (Lee et al., 2006). Immu-
noprecipitation was performed with rabbit a-acetyl CBP/p300 (no. 4771; Cell
Signaling Technology) or control immunoglobulin G (IgG) (ab46540 ChIP
grade; Abcam). Immunoprecipitated chromatin was eluted and reverse cross-
linked overnight at 65C. qPCR was performed using the MAXIMA SYBR
Green kit (Fermentas) and a 7900HT Fast Real Time PCR System. The SDS
2.4 software package was used to extract raw data. Primer sequences are
available on request.
Plasmids and Mutagenesis
Plasmids Mef2c-73k-lacZ (mef2c-lacZ), Mgn184-luciferase, pG5E1b-lucif-
erase, pRK5-MyoD, GAL4(DBD)-E12bHLH, E12-VP16, GAL4(DBD)-MyoD,
and GAL4(DBD)-MyoD(bHLH) have been described (Black et al., 1998; Dodou
et al., 2003; Heidt et al., 2007). PlasmidMef2c[-106]-73k-lacZ (no NFAT sites)
contains nucleotides 106 to +105 relative to theMef2c skeletal muscle tran-
scriptional start site. Plasmidmrf4-lacZwas generated by cloning a previously
described 390 bp region of the mouse mrf4 promoter (Black et al., 1995) into
the promoterless vector pAUG-b-gal (Rojas et al., 2008). Mouse NFATc1,
NFATc3, and NFATc4 cDNAs were subcloned into pRK5 to create expression
plasmids. A 316 bp fragment encoding the first 101 amino acids of mouse
MyoD was cloned into vector PCS2+MT to create the MyoD N-terminal
expression plasmid. Truncation and deletion mutants of MyoD and NFATc1
were generated by PCR and confirmed by sequencing; amplicons were di-
gested and subcloned into pRK5-FLAG. The p300 cDNA was obtained from
Addgene and subcloned into pRK5 for expression studies.
Cell Culture, Transfections, and Reporter Assays
Transfections were performed using Lipofectamine LTX (Invitrogen) with 3 mg
plasmid DNA per 35 mm dish. Cells were incubated in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum for 16 hr posttransfec-
tion and then were switched to DMEM with 2% horse serum for 5 days for
myotube conversion assays or for 36 hr for all other transfection experiments.
Cellular extracts were normalized and assayed for b-galactosidase or lucif-
erase activity as previously described (Heidt et al., 2007; Rojas et al., 2008).Cell ReAll transfections lacking an expression plasmid contained parental vector
DNA such that each transfection had an equivalent amount of plasmid DNA.
Coimmunoprecipitation and Western Blotting
Cells or tissues were washed in 4C PBS and then lysed and homogenized in
either cracking buffer (835 mM sucrose, 1.7% SDS, and 170 mM Tris-HCl [pH
8.8]) or radio immunoprecipitation assay buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 2 mM EDTA, 1% NP-40, and 0.1% SDS) in the presence of a protease
inhibitor cocktail (Roche) for tissue culture cells or muscle tissue, respectively.
Lysates were incubated at 4Covernight with primary antibody or isotype con-
trol and then for 2 hr with 100 mg Protein G Sepharose beads (Sigma-Aldrich).
Samples were then subjected to SDS-PAGE and western blot using standard
procedures. The following antibodies were used: rabbit a-MyoD (sc-760;
Santa Cruz Biotechnology), mouse anti-myosin fast (MY-32; Sigma-Aldrich;
1:1,000), mouse anti-slow myosin (M8421; Sigma-Aldrich; 1:1,000), mouse
a-NFATc1 (clone 7A6; BD PharMingen; 1:1,000), and rabbit a-acetyl CBP/
p300 (no. 4771; CST). For FLAG- and Myc-tagged proteins, mouse a-FLAG
(M2; Sigma-Aldrich; 1:1,000) and mouse a-myc (clone 9E10; Sigma-Aldrich;
1:1,000) were used. Mouse anti-tubulin (DSHB; 1:500) was used as a loading
control. Horseradish-peroxidase-conjugated anti-mouse (A4416; Sigma-
Aldrich; 1:1,000) was used as the secondary antibody.
Immunohistochemistry, Immunofluorescence, and Metachromatic
ATPase Staining
Immunohistochemical staining using the Vectastain Elite ABC kit (Vector Lab-
oratories; PK-6102) and immunofluorescence were performed as described
(Rojas et al., 2008). The following antibodies were used: rabbit anti-NFATc1
(sc-13033; Santa Cruz Biotechnology; 1:100), goat anti-MyoD (sc-31942;
Santa Cruz Biotechnology; 1:100), mouse anti-slow myosin (M8421; Sigma-
Aldrich; 1:250), and mouse anti-fast myosin (MY-32; Sigma-Aldrich; 1:250).
Biotin-conjugated goat anti-rabbit (Molecular Probes; 1:300), Alexa Fluor
594 donkey anti-mouse (Molecular Probes; 1:500), Alexa Fluor 488 donkey
anti-rabbit (Molecular Probes; 1:500), Alexa Fluor 594 donkey anti-goat
(Molecular Probes; 1:500), and Alexa Fluor 647 chicken anti-mouse (Molecular
Probes; 1:500) were used as secondary antibodies. Metachromatic ATPase
staining with 0.1% toluidine blue was performed as described (Ogilvie and
Feeback, 1990).
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